Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 13/20 | 0.35 |
| ▸ | CSF1R | P07333 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 3/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | CD38 | P28907 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19010342 | 0.92 | KDR (0.32) | CSF1RJAK2KDR | |
| SCHEMBL2696001 | 0.87 | JAK3 (0.50) | CSF1RJAK3IRAK4JAK2JAK1 | |
| SCHEMBL17021435 | 0.83 | AURKA (0.39) | SYKCSF1RJAK3IRAK4JAK2 | |
| SCHEMBL17021362 | 0.80 | GFER (0.48) | SYK | |
| SCHEMBL17021433 | 0.80 | CD38 (0.41) | SYKCSF1RJAK3IRAK4JAK2 | |
| SCHEMBL17021361 | 0.80 | STAT6 (0.43) | SYKJAK3JAK2JAK1TYK2 | |
| SCHEMBL17021330 | 0.79 | JAK3 (0.47) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL17021356 | 0.79 | CDC7 (0.43) | CSF1RJAK3IRAK4JAK2JAK1 | |
| SCHEMBL17021390 | 0.79 | JAK3 (0.44) | SYKJAK3JAK2JAK1TYK2 | |
| SCHEMBL17021434 | 0.78 | JAK3 (0.46) | SYKCSF1RJAK3IRAK4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| WO-2015123453-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK2, JAK3 | SYK 248/4885CSF1R 1267/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.